M Pivavarchyk

First name:
M
Last name:
Pivavarchyk
Wooters, T. E., Smith, A. M., Pivavarchyk, M., Siripurapu, K. B., McIntosh, J. M., Zhang, Z., et al. (2011). bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal Of Pharmacology, 163(2), 346-57. https://doi.org/10.1111/j.1476-5381.2011.01220.x
View
Smith, A. M., Pivavarchyk, M., Wooters, T. E., Zhang, Z., Zheng, G., McIntosh, J. M., et al. (2010). Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochemical Pharmacology, 80(3), 402-9. https://doi.org/10.1016/j.bcp.2010.03.018 (Original work published 2010)
View
Dwoskin, L. P., Pivavarchyk, M., Joyce, B. M., Neugebauer, N. M., Zheng, G., Zhang, Z., et al. Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebraska Symposium On Motivation. Nebraska Symposium On Motivation, 55, 31-63. https://doi.org/10.1007/978-0-387-78748-0_4 (Original work published 2009)
View
Beckmann, J. S., Meyer, A. C., Pivavarchyk, M., Horton, D. B., Zheng, G., Smith, A. M., et al. (2015). r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research, 40(10), 2121-30. https://doi.org/10.1007/s11064-015-1680-4
View